Merck's $3.9B SpringWorks deal, Hims & Hers' Wegovy partnership, CVS exiting Obamacare, and FDA updates on key drugs.

Paris: Sanofi has announced the closing of the sale to CD&R of a 50.0% controlling stake of its consumer healthcare business ...

Opella, Sanofi's consumer healthcare business, is expected to leverage local platforms to drive innovation and collaborate with domestic healthcare institutions to increase its presence in the country ...

Sanofi reported net cash proceeds of about 10 billion ($10.7 billion) from the deal, which it had outlined earlier in 2024.

Sanofi has completed the sale of a 50.0% controlling stake in its consumer healthcare division, Opella, to CD&R, creating a global leader in ...

Six months after entering talks with U.S. private equity firm Clayton, Dubilier & Rice (CD&R), Sanofi has closed a deal to ...

Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in Sanofi's strategy. Sanofi announces today the closing of the sale to CD&R of a 50.0% controlling ...

Opella is now a standalone company. Sanofi announced today the closing of the sale to CD&R of a 50.0% controlling stake of ...

Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in French pharma major Sanofi's strategy. Sanofi announced today the closing of the sale to US private ...

Enterogermina, the leading brand in the probiotic segment and part of Opella, Sanofi's Consumer Healthcare business unit, has launched a campaign that playfully challenges the laws of physics: The ...

In a report released today, James Quigley from Goldman Sachs maintained a Hold rating on Sanofi (SNYNF – Research Report), with a price target of €117.00. The company’s shar ...